Stocktoria
Aligos Therapeutics, Inc. ALGS
Aligos Therapeutics, Inc. (ALGS) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $2.2M at a -1106.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ALGS | Aligos Therapeutics, Inc. | 2/9 | — | — | — |
| HUMA | Humacyte, Inc. | 3/9 | — | — | — |
| OTLK | Outlook Therapeutics, Inc. | 1/9 | — | — | — |
| PLUR | Pluri Inc. | 2/9 | — | — | — |
| SCNI | Scinai Immunotherapeutics Ltd. | 2/9 | — | — | — |
| DYAI | DYADIC INTERNATIONAL INC | 1/9 | — | — | — |
| SRZN | Surrozen, Inc./DE | 2/9 | -15.54 | — | -67.4% |
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
FAQ
Is ALGS financially healthy?
Aligos Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does ALGS pay a dividend?
No, Aligos Therapeutics, Inc. does not currently pay a dividend.
How profitable is ALGS?
In FY2025, Aligos Therapeutics, Inc. had a net margin of -1106.7% and a return on equity of -45.2%.
What is the analyst price target for ALGS?
The average Wall-Street price target for Aligos Therapeutics, Inc. is $56.29, about 704.1% above the recent price, from 7 analysts.
Is ALGS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Aligos Therapeutics, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.